CASI Pharmaceuticals (NASDAQ:CASI) Announces Earnings Results, Misses Estimates By $0.06 EPS
CASI Pharmaceuticals (NASDAQ:CASI) issued its quarterly earnings data on Wednesday, November 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.06), Bloomberg Earnings reports.
Shares of NASDAQ:CASI traded down $0.13 during trading hours on Friday, hitting $3.90. 249,673 shares of the company’s stock traded hands, compared to its average volume of 347,006. CASI Pharmaceuticals has a 1 year low of $2.55 and a 1 year high of $8.89. The firm has a market capitalization of $383.53 million, a PE ratio of -21.67 and a beta of 1.46.
CASI has been the topic of several analyst reports. HC Wainwright set a $7.00 price objective on CASI Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, November 21st. ValuEngine lowered CASI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 28th. Finally, BidaskClub upgraded CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday.
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma and triple-negative breast cancer.
Further Reading: Capital gains and your 401(k) or IRA
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.